HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $73 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis reiterates a Buy rating on Celldex Therapeutics (NASDAQ:CLDX) and maintains a $73 price target.
May 31, 2023 | 1:29 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Joseph Pantginis reiterates a Buy rating on Celldex Therapeutics and maintains a $73 price target.
The Buy rating and maintained $73 price target by HC Wainwright & Co. analyst Joseph Pantginis indicates a positive outlook for Celldex Therapeutics. This news is directly related to the company and is likely to have a positive impact on its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100